IRVING, TX -- September 4, 2009 -- Reata Pharmaceuticals, Inc. announces that the company's Vice President of Finance, Jason Wilson, will be presenting a company overview on Wednesday, September 9, 2009 at the Thomas Weisel Partners 2009 Healthcare Conference at 3:15 p.m., EST.  The event will be held from September 9^th through the 11^th at the Four Seasons Hotel in Boston, MA.

 

The presentation will highlight clinical data from the company’s lead program, bardoxolone methyl, an orally available, first-in-class Antioxidant Inflammation Modulator (AIM) in Phase 2 development for chronic kidney disease (CKD).  The drug, also known as RTA 402, resolves inflammation by activating the anti-oxidant Nrf2 and addresses an unmet need for potent, oral anti-inflammatory agents.  Mr. Wilson will present the results of the company's two successfully completed Phase 2a studies, in which the drug produced an unprecedented improvement in kidney function in diabetics with advanced CKD, with significant dose- and time-dependent improvements seen in the primary endpoint. 

 

Mr. Wilson will also describe Reata's clinical development plan for bardoxolone methyl, including an update on the ongoing Phase 2b trial in Stage 3b and 4 CKD patients, along with upcoming milestones and partnering objectives. 

 

CKD is a progressive loss of kidney function over a period of months or years, which can be caused by a number of conditions, including diabetes and high blood pressure.  As kidney disease gets worse, waste products can build to high levels in the blood and patients may develop complications like high blood pressure, anemia (low blood count), weak bones, poor nutritional health and nerve damage.  CKD also increases the risk of having heart and blood vessel disease.  As kidney disease progresses, it eventually leads to kidney failure, requiring dialysis or a kidney transplant.

 

 

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases. Reata is the leader in discovering and developing novel anti-inflammatory drugs targeting Nrf2, which controls the body's production of antioxidant and detoxification enzymes and has been shown to protect against a broad range of diseases associated with inflammation and oxidative stress.  Reata is developing a portfolio of AIMs for a variety of inflammation-related diseases.  The company's most advanced program is in late-stage clinical development for the treatment of CKD, a progressive condition affecting more than 26 million Americans.  For more information, visit www.reatapharma.com.